During the past decade, BAG Freiberg-Richter, Jacobasch, Illmer, Wolf; Gemeinschaftspraxis Hämatologie-Onkologie conducted 29 clinical trials. In the 10-year time frame, 29 clinical trials started and 15 clinical trials were completed, i.e. on average, 51.7% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 8 clinical trials were completed. i.e. 80% of trials that started reached the finish line.

Out of the total clinical trials conducted in "BAG Freiberg-Richter, Jacobasch, Illmer, Wolf; Gemeinschaftspraxis Hämatologie-Onkologie" #1 sponsor was "Hoffmann-La Roche" with 12 trials, followed by "German CLL Study Group" with 5 trials sponsored, "AIO-Studien-gGmbH" with 3 trials sponsored, "University of Erlangen-Nürnberg Medical School" with 3 trials sponsored and "iOMEDICO AG" with 3 trials sponsored. Other sponsors include 13 different institutions and companies that sponsored additional 19 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "BAG Freiberg-Richter, Jacobasch, Illmer, Wolf; Gemeinschaftspraxis Hämatologie-Onkologie" #1 collaborator was "Roche Pharma AG" with 4 trials as a collaborator, "AbbVie" with 3 trials as a collaborator, "German CLL Study Group" with 3 trials as a collaborator, "Bristol-Myers Squibb" with 2 trials as a collaborator and "Alliance Foundation Trials (AFT)" with 1 trials as a collaborator. Other collaborators include 20 different institutions and companies that were collaborators in the rest 30 trials.

According to Clinical.Site data, the most researched conditions in "BAG Freiberg-Richter, Jacobasch, Illmer, Wolf; Gemeinschaftspraxis Hämatologie-Onkologie" are "Chronic Lymphocytic Leukemia" (5 trials), "Breast Cancer" (4 trials), "Chronic Lymphoid Leukemia" (2 trials), "Colorectal Cancer" (2 trials) and "Head and Neck Squamous Cell Carcinoma" (2 trials). Many other conditions were trialed in "BAG Freiberg-Richter, Jacobasch, Illmer, Wolf; Gemeinschaftspraxis Hämatologie-Onkologie" in a lesser frequency.

Most popular intervention types in "BAG Freiberg-Richter, Jacobasch, Illmer, Wolf; Gemeinschaftspraxis Hämatologie-Onkologie" are "Drug" (36 trials), "Combination Product" (3 trials), "Biological" (2 trials), "Other" (2 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "Cyclophosphamide" (6 trials), "Rituximab" (6 trials), "Fludarabine" (5 trials), "Obinutuzumab" (5 trials) and "Bendamustine" (4 trials). Other intervention names were less common.

The vast majority of trials in "BAG Freiberg-Richter, Jacobasch, Illmer, Wolf; Gemeinschaftspraxis Hämatologie-Onkologie" are 40 trials for "All" genders and 4 trials for "Female" genders.

Currently, there are NaN active trials in "BAG Freiberg-Richter, Jacobasch, Illmer, Wolf; Gemeinschaftspraxis Hämatologie-Onkologie". 1 are not yet recruiting, 7 are recruiting, 9 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 23 completed trials in BAG Freiberg-Richter, Jacobasch, Illmer, Wolf; Gemeinschaftspraxis Hämatologie-Onkologie, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in BAG Freiberg-Richter, Jacobasch, Illmer, Wolf; Gemeinschaftspraxis Hämatologie-Onkologie, 2 "Phase 1" clinical trials were conducted, 15 "Phase 2" clinical trials and 23 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".

BAG Freiberg-Richter, Jacobasch, Illmer, Wolf; Gemeinschaftspraxis Hämatologie-Onkologie has several departments that took part in Clinical trials: "BAG Freiberg-Richter, Jacobasch, Wolf, Illmer" - 3 trials